BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen K, Wei W, Liu L, Deng ZJ, Li L, Liang XM, Guo PP, Qi LN, Zhang ZM, Gong WF, Huang S, Yuan WP, Ma L, Xiang BD, Li LQ, Zhong JH. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunol Immunother 2021. [PMID: 34559308 DOI: 10.1007/s00262-021-03060-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Qian Y, Gong L, Li S, Mao K, Li X, Liao G. Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. Front Oncol 2022;12:879454. [DOI: 10.3389/fonc.2022.879454] [Reference Citation Analysis]
2 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]